Reviva Pharmaceuticals narrows path to Brilaroxazine FDA submission with 2026 Phase 3 launch
Reviva Pharmaceuticals Holdings (NASDAQ:RVPH), a clinical-stage pharmaceutical company developing next-generation therapies for central nervous system (CNS) disorders, today announced its financial results and corporate updates for the full year ended December 31, 2025.










